-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Allogene Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q4 2017 to Q4 2024.
- Allogene Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending December 31, 2024 was $994K.
- Allogene Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending December 31, 2024 was $16.1M, a 3301% increase year-over-year.
- Allogene Therapeutics, Inc. annual Nonoperating Income (Expense) for 2024 was $16.1M, a 3301% increase from 2023.
- Allogene Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was $472K.
- Allogene Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was -$4.88M, a 162% decline from 2021.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)